X4 Pharma Q1 net income $0.3M on $28.8M revenue; XOLREMDI sales $3.5M since launch; 4WARD trial on track

X4 Pharmaceuticals, Inc

2025-Q1 EPS reported $0.04 revenue$900,000

Q1 net income $0.3M vs loss $51.8M YoY; revenue $28.8M included $27.9M license fee from Norgine.
XOLREMDI cumulative U.S. net sales $3.5M since May 2024 launch through March 2025.
Phase 3 4WARD CN trial full enrollment expected 3Q/4Q 2025; top-line data in 2H 2026.
Strategic restructuring to cut annual spending by $30-35M; cash $87.7M funds ops into 1H 2026.
Completed 1-for-30 reverse stock split effective April 28, 2025; shares reduced from ~173.6M to ~5.8M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.